Critical Comparison: BIOLASE (BLTI) & Cogentix Medical (CGNT)

BIOLASE (NASDAQ: BLTI) and Cogentix Medical (NASDAQ:CGNT) are both small-cap advanced medical equipment & technology – nec companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for BIOLASE and Cogentix Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BIOLASE 0 0 0 0 N/A
Cogentix Medical 0 0 2 0 3.00

Cogentix Medical has a consensus price target of $4.50, indicating a potential upside of 73.08%. Given Cogentix Medical’s higher probable upside, analysts plainly believe Cogentix Medical is more favorable than BIOLASE.

Insider & Institutional Ownership

12.5% of Cogentix Medical shares are held by institutional investors. 62.7% of Cogentix Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

BIOLASE has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500. Comparatively, Cogentix Medical has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Earnings and Valuation

This table compares BIOLASE and Cogentix Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
BIOLASE N/A N/A N/A ($0.33) -1.76
Cogentix Medical $51.85 million 3.05 -$22.09 million ($0.41) -6.34

BIOLASE has higher revenue, but lower earnings than Cogentix Medical. Cogentix Medical is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BIOLASE and Cogentix Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BIOLASE -34.01% -151.86% -43.37%
Cogentix Medical -36.14% -11.55% -10.12%

Summary

Cogentix Medical beats BIOLASE on 7 of the 10 factors compared between the two stocks.

About BIOLASE

BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

About Cogentix Medical

Cogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

Receive News & Ratings for BIOLASE Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply